Literature DB >> 28237138

Optical coherence tomography angiography in chorioretinal disorders.

Paulo Ricardo Chaves De Oliveira1, Alan Richard Berger2, David Robert Chow3.   

Abstract

Optical coherence tomography angiography (OCTA) is a novel imaging modality that incorporates blood motion contrast to create angiograms of the retinal vasculature in a noninvasive manner, without the use of dye. It is a safe procedure and can be repeated as frequently as desired. The use of OCTA for delineation of choroidal neovascular membranes, for the study of microvascular abnormalities in diabetic patients, to assess nonperfused areas in retinal occlusions and vascular changes in macular telangiectasia are some of the potential OCTA applications. However, it is not free of drawbacks. Major limitations include the small field of view and its great sensitivity to movement. As a result, it is prone to motion artifacts, leading to poor-quality images. The scope of the body literature regarding this new modality rapidly increases as we learn how to better use this technology. Our objective is to point overall aspects of OCTA, including its limitations and review some of its initial reports on chorioretinal diseases.
Copyright © 2017 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28237138     DOI: 10.1016/j.jcjo.2016.07.015

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  2 in total

1.  Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations.

Authors:  Mehmet Bulut; Melih Akıdan; Onursal Gözkaya; Muhammet Kazım Erol; Ayşe Cengiz; Hasan Fatih Çay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-29       Impact factor: 3.117

Review 2.  In vivo retinal imaging in translational regenerative research.

Authors:  Ifat Sher; Daniel Moverman; Hadas Ketter-Katz; Elad Moisseiev; Ygal Rotenstreich
Journal:  Ann Transl Med       Date:  2020-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.